Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.

Parkinsonism & related disorders - 1 Oct 2024

Thaler Avner, Anis Saar, Ponger Penina, Fay-Karmon Tsviya, Livneh Vered, Faust-Socher Achinoam, Greenbaum Lior, Reiner Johnathan, Hilel Ariela, Shabtai Hertzel, Alcalay Roy N, Djaldetti Ruth, Hassin-Baer Sharon, Ezra Adi, Mirelman Anat, Giladi Nir, Gurevich Tanya

Abstract excerpt

BACKGROUND: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). OBJECTIVE: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. METHODS: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. RESULTS: Fifty-two iPD, 15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antiparkinson Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Glucosylceramidase

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Levodopa

Share to Parkinson Disease

Source

Identifiers

PMID: 39208588
DOI: 10.1016/j.parkreldis.2024.107115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.PMID 39208588Read ↗

Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study.Semantic proximity Read ↗

Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.Semantic proximity Read ↗

Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Semantic proximity Read ↗

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.Semantic proximity Read ↗

Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.Semantic proximity Read ↗

Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants.Semantic proximity Read ↗

A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.Semantic proximity Read ↗

GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.Semantic proximity Read ↗

Short-and long-term responsiveness of deep brain stimulation on motor and cognitive outcomes in GBA vs. Non-GBA parkinson's disease: a systematic review and meta-analysis of observational studies.Semantic proximity Read ↗

Device-aided therapies (DATs) in Parkinson’s disease (PD). The DATs-PD GETM Spanish Registry Protocol StudySemantic proximity Read ↗

Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.Semantic proximity Read ↗

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.